Health

J&J recipients 3.5 times more likely to develop rare blood clots

Americans who received the one-dose Johnson & Johnson COVID-19 vaccine were 3.5 times as likely to develop rare blood clots compared to the general population, study finds

Published

on

  • Recipients of the J&J COVID-19 vaccine are 3.5 times as likely to develop a rare, deadly, blood clotting condition than the general population, a new study finds
  • Researchers found that 8.5 J&J recipients developed the clots for every 100,000 person years, compared to only 2.5 out of the general population
  • Researchers found that women between aged 30 and 64 were most at risk of developing the clotting 
  • Authorization of the vaccine was paused for ten days during April due to concerns of the blood clotting developing in women 
  • Cerebral venous sinus thrombosis, or CVST, is a dangerous condition that can cause a person to suffer stroke, or even die

Johnson & Johnson‘s COVID-19 vaccine increases a person’s risk of developing rare blood clots, a new study suggests.

Researchers from the Mayo Clinic in Rochester, Minnesota, compared data from the general population before the pandemic to data gathered from reported vaccine side-effects suffered by Americans.

They found that a person who received the vaccine was 3.5 times as likely to develop brain blood clots as an average person before the pandemic.

Blood clotting, and specifically cerebral venous sinus thrombosis (CVST) is a well known side-effect of the J&J vaccine, and the discovery of this risk was the reason usage of the vaccine was paused in April.

However, the team insists the risk is rare and that the findings must be looked at in the context of the effectiveness of the vaccine in preventing severe cases COVID-19.

Researchers, who published their findings in JAMA Internal Medicine on Monday, gathered data from Olmstead, County, Minnesota – a county of around 158,000 people 90 miles southeast of Minneapolis – from 2001 to 2015.

They then used the Centers for Disease Control and Prevention’s Vaccine Adverse Event Reporting System (VAERS) to find diagnoses of blood clots in people who received the J&J vaccine between the jab’s approval date at the end of February 2021 to May 7. 

During the 14-year period, there were 39 Olmstead residents who developed CVST – a rare, potentially deadly, blood clotting condition that can form in a person’s brain.

Of that group, 29 had a risk factor within the 92 days proceeding development of the blood clot, such as infection, active cancer, or oral contraceptives for women.

Adjusted for population, there were 2.46 cases of CVST out of every 100,000 person-years of the residents of Olmstead County developed blood clotting during that period.

Read more on Daily Mail

Click to comment

Trending

Exit mobile version